Through Consolidation Durvalumab, Limited-Stage SCLC Receives a New Standard of Care.

Published Date: 07 Jun 2024

In the durvalumab group, the median OS was 55.9 months, while in the placebo group it was 33.4 months.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Study finds primary-care doctors often overlook prostate cancer risk in Black men

2.

Because of the Medicare mail-order drug rule, oncologists run the risk of self-referral violations.

3.

FDA Approves New Drug Combo for RR Multiple Myeloma

4.

Year in Review: Chronic Lymphocytic Leukemia

5.

What Dolph Lundgren's journey from terminal diagnosis to 'cancer free' can tell us about cancer care


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot